ES2991800T3 - Oligonucleótidos para inducir la expresión del UBE3A paterno - Google Patents

Oligonucleótidos para inducir la expresión del UBE3A paterno Download PDF

Info

Publication number: ES2991800T3
Authority: ES; Spain
Prior art keywords: oligonucleotide; rna; conjugate; nucleosides; modified
Prior art date: 2015-11-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES23152543T

Other languages

English (en)

Spanish (es)

Inventor

Veronica Costa

Maj Hedtjärn

Marius Hoener

Ravi Jagasia

Mads Aaboe Jensen

Christoph Patsch

Lykke Pedersen

Søren Vestergaard Rasmussen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

F Hoffmann La Roche AG

Original Assignee

F Hoffmann La Roche AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2016-11-11

Publication date

2024-12-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57345910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2991800(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-11 Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG

2024-12-04 Application granted granted Critical

2024-12-04 Publication of ES2991800T3 publication Critical patent/ES2991800T3/es

Status Active legal-status Critical Current

2036-11-11 Anticipated expiration legal-status Critical

Links

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Immunology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Developmental Biology & Embryology (AREA)

ES23152543T 2015-11-12 2016-11-11 Oligonucleótidos para inducir la expresión del UBE3A paterno Active ES2991800T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP15194367		2015-11-12
EP16189502		2016-09-19

Publications (1)

Publication Number	Publication Date
ES2991800T3 true ES2991800T3 (es)	2024-12-04

Family

ID=57345910

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES23152543T Active ES2991800T3 (es)	2015-11-12	2016-11-11	Oligonucleótidos para inducir la expresión del UBE3A paterno
ES16798440T Active ES2852998T4 (es)	2015-11-12	2016-11-11	Oligonucleótidos para inducir la expresión de UBE3A paterno

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES16798440T Active ES2852998T4 (es)	2015-11-12	2016-11-11	Oligonucleótidos para inducir la expresión de UBE3A paterno

Country Status (30)

Country	Link
US (10)	US10494633B2 (2)
EP (5)	EP4220360B9 (2)
JP (7)	JP2018533362A (2)
KR (4)	KR102185465B1 (2)
CN (5)	CN116064539A (2)
AU (4)	AU2016352836B2 (2)
CA (1)	CA3004799C (2)
CL (3)	CL2018001189A1 (2)
CO (1)	CO2018004550A2 (2)
CR (3)	CR20220077A (2)
DK (2)	DK3374509T3 (2)
ES (2)	ES2991800T3 (2)
FI (1)	FI4220360T3 (2)
HK (2)	HK1258309A1 (2)
HR (2)	HRP20241138T1 (2)
HU (2)	HUE053197T2 (2)
IL (4)	IL300119B1 (2)
LT (2)	LT3374509T (2)
MA (1)	MA67580B1 (2)
MX (4)	MX2018004978A (2)
PE (2)	PE20210451A1 (2)
PH (1)	PH12018501005A1 (2)
PL (2)	PL4220360T3 (2)
RS (2)	RS61529B9 (2)
RU (1)	RU2742007C2 (2)
SG (1)	SG11201803951QA (2)
SI (2)	SI3374509T1 (2)
UA (1)	UA125963C2 (2)
WO (3)	WO2017081223A1 (2)
ZA (1)	ZA201802494B (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102282155B (zh)	2008-12-02	2017-06-09	日本波涛生命科学公司	磷原子修饰的核酸的合成方法
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
NZ714887A (en)	2009-09-11	2019-07-26	Ionis Pharmaceuticals Inc	Modulation of huntingtin expression
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
CN103796657B (zh)	2011-07-19	2017-07-11	波涛生命科学有限公司	合成官能化核酸的方法
WO2014004572A2 (en)	2012-06-25	2014-01-03	Isis Pharmaceuticals, Inc.	Modulation of ube3a-ats expression
PL2872485T3 (pl)	2012-07-13	2021-05-31	Wave Life Sciences Ltd.	Asymetryczna grupa pomocnicza
KR102213609B1 (ko)	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt)	2014-01-16	2017-10-03	Wave Life Sciences Ltd	Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
US10400243B2 (en)	2014-11-25	2019-09-03	Ionis Pharmaceuticals, Inc.	Modulation of UBE3A-ATS expression
LT3374509T (lt)	2015-11-12	2021-03-10	F. Hoffmann-La Roche Ag	Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
KR102723989B1 (ko)	2017-12-01	2024-11-01	더 텍사스 에이 & 엠 유니버시티 시스템	엔젤만 증후군 안티센스 치료
WO2019157531A1 (en)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
CN108795935B (zh) *	2018-05-23	2022-06-21	中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心)	日本血吸虫SjELAV-like 1基因的siRNA及其应用
WO2020061528A1 (en) *	2018-09-21	2020-03-26	University Of Connecticut	Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
EP3911957A1 (en) *	2019-01-17	2021-11-24	F. Hoffmann-La Roche AG	E3 ubiquitin ligase (ube3a) protein targets
TW202102516A (zh) *	2019-02-20	2021-01-16	丹麥商羅氏創新中心哥本哈根有限公司	膦醯基乙酸酯間隙子寡核苷酸
PT3947684T (pt) *	2019-03-29	2025-05-19	Ionis Pharmaceuticals Inc	Compostos e métodos para modular ube3a‑ats
US12465655B2 (en) *	2019-05-22	2025-11-11	The University Of North Carolina At Chapel Hill	UBE3A genes and expression cassettes and their use
EP3976765A1 (en)	2019-05-28	2022-04-06	F. Hoffmann-La Roche AG	Method to generate monocytic progenitor cells
TW202204607A (zh) *	2020-04-16	2022-02-01	英商羅斯林科技有限公司	誘導性多功能幹細胞(iPSC)之誘導
US20230212572A1 (en) *	2020-06-09	2023-07-06	Roche Innovation Center Copenhagen A/S	Guanosine Analogues for Use in Therapeutics Polynucleotides
EP4282651A4 (en)	2021-01-21	2024-12-18	Fujimori Kogyo Co., Ltd.	MULTILAYER FILM AND PACKAGING BAGS
CN119173632A (zh)	2022-05-10	2024-12-20	豪夫迈·罗氏有限公司	靶向cfp-elk1基因间区域的反义寡核苷酸
EP4705457A2 (en)	2023-05-04	2026-03-11	F. Hoffmann-La Roche AG	Oligonucleotides capable of upregulating glucocerebrosidase expression
WO2025100980A1 (ko) *	2023-11-08	2025-05-15	한국과학기술원	Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도
WO2025125542A1 (en)	2023-12-15	2025-06-19	F. Hoffmann-La Roche Ag	Intrathecal dosage method
WO2025213123A1 (en) *	2024-04-05	2025-10-09	Encoded Therapeutics, Inc.	Methods and compositions for increasing expression of ube3a
WO2025217466A1 (en) *	2024-04-11	2025-10-16	Ultragenyx Pharmaceutical Inc.	Dosing regimens for antisense treatment of angelman syndrome

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4373084A (en)	1981-07-07	1983-02-08	E. I. Du Pont De Nemours And Company	Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom
DE69233046T2 (de)	1991-10-24	2004-03-04	Isis Pharmaceuticals, Inc., Carlsfeld	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6617162B2 (en)	2001-12-18	2003-09-09	Isis Pharmaceuticals, Inc.	Antisense modulation of estrogen receptor alpha expression
JP4236812B2 (ja)	1997-09-12	2009-03-11	エクシコンエ／エス	オリゴヌクレオチド類似体
US6238921B1 (en)	1998-03-26	2001-05-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human mdm2 expression
CA2702148C (en) *	1999-01-06	2014-03-04	Genenews Inc.	Method of profiling gene expression in a human subject having an infectious disease
ES2234563T5 (es)	1999-02-12	2018-01-17	Daiichi Sankyo Company, Limited	Nuevos análogos de nucleósidos y oligonucleótidos
US7053207B2 (en)	1999-05-04	2006-05-30	Exiqon A/S	L-ribo-LNA analogues
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
EP1234174A1 (en)	1999-12-02	2002-08-28	Myriad Genetics, Inc.	Protein-protein interactions
US6300132B1 (en)	1999-12-17	2001-10-09	Isis Pharmaceuticals, Inc.	Antisense inhibition of telomeric repeat binding factor 2 expression
WO2001092582A1 (en) *	2000-06-01	2001-12-06	Genaissance Pharmaceuticals, Inc.	Haplotypes of the ube3a gene
US20030087855A1 (en)	2001-09-13	2003-05-08	Isis Pharmaceuticals Inc.	Antisense modulation of protein kinase R expression
EP2221376B1 (en)	2001-06-21	2012-11-21	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US20050124572A1 (en) *	2002-06-17	2005-06-09	Freier Susan M.	Compositions and their uses directed to signal tranducers
WO2004016754A2 (en)	2002-08-14	2004-02-26	Pharmacia Corporation	ANTISENSE MODULATION OF Nav1.3 EXPRESSION
JP2006500066A (ja) *	2002-09-25	2006-01-05	ファルマシア・コーポレーション	ミクロソームのプロスタグランジンｅ２シンターゼ発現のアンチセンス調節
WO2004046160A2 (en)	2002-11-18	2004-06-03	Santaris Pharma A/S	Amino-lna, thio-lna and alpha-l-oxy-ln
KR20060115351A (ko) *	2003-08-29	2006-11-08	위스콘신 얼럼나이 리서어치 화운데이션	영장류 배아 줄기 세포 기원의 신경 줄기 세포, 운동 뉴런및 도파민 뉴런의 시험관내 분화 방법
WO2007031091A2 (en)	2005-09-15	2007-03-22	Santaris Pharma A/S	Rna antagonist compounds for the modulation of p21 ras expression
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
WO2007090071A2 (en)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
JP2009536222A (ja)	2006-05-05	2009-10-08	アイシスファーマシューティカルズ，インコーポレーテッド	Ｐｃｓｋ９の発現を調節するための化合物および方法
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
DK2149605T3 (da)	2007-03-22	2013-09-30	Santaris Pharma As	Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
PE20090064A1 (es)	2007-03-26	2009-03-02	Novartis Ag	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
CA2688321A1 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en)	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en)	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009090182A1 (en)	2008-01-14	2009-07-23	Santaris Pharma A/S	C4'-substituted - dna nucleotide gapmer oligonucleotides
US9290534B2 (en)	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
DK2356129T3 (da)	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
WO2010096496A2 (en) *	2009-02-17	2010-08-26	Memorial Sloan-Kettering Cancer Center	Methods of neural conversion of human embryonic stem cells
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
JP5843775B2 (ja) *	2009-10-13	2016-01-13	ステムセルテクノロジーズインコーポレーティッド	幹細胞を分化させるための重量オスモル濃度の操作法
CN102869776B (zh)	2009-12-23	2017-06-23	库尔纳公司	通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
EP2580228B1 (en)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
JP5998131B2 (ja)	2010-07-14	2016-09-28	カッパーアールエヌエー，インコーポレイテッド	Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
EP2595663A4 (en)	2010-07-19	2014-03-05	Isis Pharmaceuticals Inc	MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
CA2807226A1 (en) *	2010-08-19	2012-02-23	F.Hoffmann-La Roche Ag	Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
US9714427B2 (en)	2010-11-11	2017-07-25	The University Of North Carolina At Chapel Hill	Methods and compositions for unsilencing imprinted genes
CA2817960C (en)	2010-11-17	2020-06-09	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
DK2694644T3 (en) *	2011-03-30	2018-04-16	Cellular Dynamics Int Inc	Priming of pluripotent stem cells for neural differentiation
RU2013150331A (ru)	2011-04-20	2015-05-27	Рош Гликарт Аг	СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
WO2013033230A1 (en)	2011-08-29	2013-03-07	Isis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
EP2753631A1 (en)	2011-09-07	2014-07-16	Marina Biotech, Inc.	Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
EP2850092B1 (en)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
WO2014004572A2 (en) *	2012-06-25	2014-01-03	Isis Pharmaceuticals, Inc.	Modulation of ube3a-ats expression
CN104837996A (zh)	2012-11-15	2015-08-12	罗氏创新中心哥本哈根有限公司	抗apob反义缀合物化合物
WO2014077693A1 (en)	2012-11-16	2014-05-22	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	Means and methods for reducing an effect of aging in a mammalian cell
ES2939807T3 (es) *	2014-03-21	2023-04-27	Fujifilm Cellular Dynamics Inc	Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización
LT3374509T (lt) *	2015-11-12	2021-03-10	F. Hoffmann-La Roche Ag	Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
BR112019027692A2 (pt)	2017-06-28	2020-11-24	University Of South Florida	gene ube3a modificado para uma abordagem terapêutica genética para a síndrome de angelman
KR102723989B1 (ko)	2017-12-01	2024-11-01	더 텍사스 에이 & 엠 유니버시티 시스템	엔젤만 증후군 안티센스 치료
AU2019212849B2 (en)	2018-01-26	2024-02-29	F. Hoffmann-La Roche Ag	Radiolabelled oligonucleotides and process for their preparation
PT3947684T (pt) *	2019-03-29	2025-05-19	Ionis Pharmaceuticals Inc	Compostos e métodos para modular ube3a‑ats

2016
- 2016-11-11 LT LTEP16798440.0T patent/LT3374509T/lt unknown
- 2016-11-11 ES ES23152543T patent/ES2991800T3/es active Active
- 2016-11-11 CN CN202211275954.4A patent/CN116064539A/zh active Pending
- 2016-11-11 HR HRP20241138TT patent/HRP20241138T1/hr unknown
- 2016-11-11 WO PCT/EP2016/077383 patent/WO2017081223A1/en not_active Ceased
- 2016-11-11 DK DK16798440.0T patent/DK3374509T3/da active
- 2016-11-11 UA UAA201806476A patent/UA125963C2/uk unknown
- 2016-11-11 CR CR20220077A patent/CR20220077A/es unknown
- 2016-11-11 HU HUE16798440A patent/HUE053197T2/hu unknown
- 2016-11-11 MA MA67580A patent/MA67580B1/fr unknown
- 2016-11-11 CN CN201680066253.6A patent/CN108291226B/zh active Active
- 2016-11-11 CR CR20200118A patent/CR20200118A/es unknown
- 2016-11-11 LT LTEP23152543.7T patent/LT4220360T/lt unknown
- 2016-11-11 CR CR20180264A patent/CR20180264A/es unknown
- 2016-11-11 FI FIEP23152543.7T patent/FI4220360T3/fi active
- 2016-11-11 JP JP2018521350A patent/JP2018533362A/ja active Pending
- 2016-11-11 HR HRP20210227TT patent/HRP20210227T1/hr unknown
- 2016-11-11 WO PCT/EP2016/077429 patent/WO2017081250A1/en not_active Ceased
- 2016-11-11 CN CN201680065987.2A patent/CN108350431A/zh active Pending
- 2016-11-11 KR KR1020187013292A patent/KR102185465B1/ko active Active
- 2016-11-11 HK HK19100676.0A patent/HK1258309A1/zh unknown
- 2016-11-11 KR KR1020207033999A patent/KR102482440B1/ko active Active
- 2016-11-11 HK HK19100670.6A patent/HK1258434A1/zh unknown
- 2016-11-11 MX MX2018004978A patent/MX2018004978A/es unknown
- 2016-11-11 PE PE2020000810A patent/PE20210451A1/es unknown
- 2016-11-11 PL PL23152543.7T patent/PL4220360T3/pl unknown
- 2016-11-11 CN CN201680066009.XA patent/CN108350432A/zh active Pending
- 2016-11-11 PL PL16798440T patent/PL3374509T3/pl unknown
- 2016-11-11 IL IL300119A patent/IL300119B1/en unknown
- 2016-11-11 CA CA3004799A patent/CA3004799C/en active Active
- 2016-11-11 JP JP2018524194A patent/JP6751142B2/ja active Active
- 2016-11-11 EP EP23152543.7A patent/EP4220360B9/en active Active
- 2016-11-11 CN CN202211275978.XA patent/CN116064540A/zh active Pending
- 2016-11-11 ES ES16798440T patent/ES2852998T4/es active Active
- 2016-11-11 KR KR1020227045154A patent/KR102840652B1/ko active Active
- 2016-11-11 SG SG11201803951QA patent/SG11201803951QA/en unknown
- 2016-11-11 KR KR1020257024980A patent/KR20250121139A/ko active Pending
- 2016-11-11 IL IL325248A patent/IL325248A/en unknown
- 2016-11-11 EP EP16797824.6A patent/EP3374498A1/en not_active Withdrawn
- 2016-11-11 EP EP16798672.8A patent/EP3374499A1/en not_active Withdrawn
- 2016-11-11 HU HUE23152543A patent/HUE067905T2/hu unknown
- 2016-11-11 RU RU2018119315A patent/RU2742007C2/ru active
- 2016-11-11 AU AU2016352836A patent/AU2016352836B2/en active Active
- 2016-11-11 WO PCT/EP2016/077435 patent/WO2017081254A1/en not_active Ceased
- 2016-11-11 JP JP2018521433A patent/JP7066609B2/ja not_active Expired - Fee Related
- 2016-11-11 IL IL281211A patent/IL281211B2/en unknown
- 2016-11-11 RS RS20210241A patent/RS61529B9/sr unknown
- 2016-11-11 PE PE2018000752A patent/PE20181157A1/es unknown
- 2016-11-11 RS RS20241003A patent/RS66036B1/sr unknown
- 2016-11-11 SI SI201631093T patent/SI3374509T1/sl unknown
- 2016-11-11 SI SI201631843T patent/SI4220360T1/sl unknown
- 2016-11-11 EP EP20204481.4A patent/EP3798307A1/en active Pending
- 2016-11-11 DK DK23152543.7T patent/DK4220360T3/da active
- 2016-11-11 EP EP16798440.0A patent/EP3374509B1/en active Active
- 2016-11-14 US US15/351,113 patent/US10494633B2/en active Active
2018
- 2018-04-03 IL IL258488A patent/IL258488B/en active IP Right Grant
- 2018-04-16 ZA ZA2018/02494A patent/ZA201802494B/en unknown
- 2018-04-23 MX MX2022016381A patent/MX2022016381A/es unknown
- 2018-04-23 MX MX2022016377A patent/MX2022016377A/es unknown
- 2018-04-23 MX MX2022016376A patent/MX2022016376A/es unknown
- 2018-04-26 CO CONC2018/0004550A patent/CO2018004550A2/es unknown
- 2018-05-03 CL CL2018001189A patent/CL2018001189A1/es unknown
- 2018-05-08 PH PH12018501005A patent/PH12018501005A1/en unknown
- 2018-05-11 US US15/977,970 patent/US20190154664A1/en not_active Abandoned
- 2018-05-11 US US15/977,895 patent/US20190144824A1/en not_active Abandoned
2019
- 2019-04-18 US US16/388,714 patent/US10739332B2/en active Active
- 2019-10-24 US US16/663,024 patent/US10718753B2/en active Active
2020
- 2020-04-02 CL CL2020000889A patent/CL2020000889A1/es unknown
- 2020-05-29 AU AU2020203573A patent/AU2020203573B2/en active Active
- 2020-07-20 US US16/933,445 patent/US11320421B2/en active Active
- 2020-08-12 JP JP2020136397A patent/JP7279000B2/ja active Active
2021
- 2021-07-08 JP JP2021113496A patent/JP2021191262A/ja active Pending
- 2021-08-13 CL CL2021002159A patent/CL2021002159A1/es unknown
2022
- 2022-01-21 US US17/581,089 patent/US11852627B2/en active Active
- 2022-08-05 AU AU2022211910A patent/AU2022211910B2/en active Active
2023
- 2023-01-25 AU AU2023200410A patent/AU2023200410B2/en active Active
- 2023-01-25 JP JP2023009553A patent/JP2023052630A/ja active Pending
- 2023-02-22 US US18/172,707 patent/US12259380B2/en active Active
- 2023-10-20 US US18/491,513 patent/US12566172B2/en active Active
2024
- 2024-11-11 JP JP2024196762A patent/JP2025024060A/ja active Pending
2025
- 2025-07-02 US US19/258,035 patent/US12596118B2/en active Active

Also Published As

Publication number	Publication date
US20200057052A1 (en)	2020-02-20
WO2017081254A1 (en)	2017-05-18
LT3374509T (lt)	2021-03-10
RU2018119315A3 (2)	2020-03-26
MA67580B1 (fr)	2024-09-30
AU2022211910A1 (en)	2022-11-10
US10739332B2 (en)	2020-08-11
AU2016352836A1 (en)	2018-04-26
KR20230008233A (ko)	2023-01-13
EP4220360A2 (en)	2023-08-02
CN116064539A (zh)	2023-05-05
US12566172B2 (en)	2026-03-03
LT4220360T (lt)	2024-09-10
EP3374509A1 (en)	2018-09-19
DK3374509T3 (da)	2021-02-15
KR20250121139A (ko)	2025-08-11
CO2018004550A2 (es)	2018-11-22
US20240085402A1 (en)	2024-03-14
US12596118B2 (en)	2026-04-07
RU2018119315A (ru)	2019-12-13
RS61529B9 (sr)	2024-04-30
JP2025024060A (ja)	2025-02-19
JP2023052630A (ja)	2023-04-11
IL258488A (en)	2018-05-31
IL325248A (en)	2026-02-01
CL2021002159A1 (es)	2022-03-11
US20250116656A2 (en)	2025-04-10
JP2018533954A (ja)	2018-11-22
US20190154664A1 (en)	2019-05-23
ZA201802494B (en)	2024-01-31
JP2019500851A (ja)	2019-01-17
US11852627B2 (en)	2023-12-26
JP2021003113A (ja)	2021-01-14
KR20200137027A (ko)	2020-12-08
SG11201803951QA (en)	2018-06-28
JP7066609B2 (ja)	2022-05-13
KR102482440B1 (ko)	2022-12-29
US20200348286A1 (en)	2020-11-05
KR102185465B1 (ko)	2020-12-03
EP3374509B1 (en)	2020-12-16
MX2018004978A (es)	2018-07-06
KR102840652B1 (ko)	2025-08-04
HK1258309A1 (zh)	2019-11-08
CR20200118A (es)	2021-04-21
US20220146496A1 (en)	2022-05-12
CA3004799C (en)	2024-05-14
EP4220360B1 (en)	2024-06-26
IL300119B1 (en)	2026-01-01
IL300119A (en)	2023-03-01
AU2020203573B2 (en)	2022-07-07
US11320421B2 (en)	2022-05-03
HK1253325A1 (zh)	2019-06-14
JP6751142B2 (ja)	2020-09-02
IL281211B1 (en)	2023-09-01
JP2021191262A (ja)	2021-12-16
EP3374499A1 (en)	2018-09-19
MX2022016377A (es)	2023-01-30
AU2016352836B2 (en)	2020-06-25
HRP20210227T1 (hr)	2021-03-19
UA125963C2 (uk)	2022-07-20
US12259380B2 (en)	2025-03-25
PE20210451A1 (es)	2021-03-08
PH12018501005A1 (en)	2019-01-28
US10494633B2 (en)	2019-12-03
FI4220360T3 (fi)	2024-08-27
CN108350431A (zh)	2018-07-31
CN108291226A (zh)	2018-07-17
IL281211A (en)	2021-04-29
HUE067905T2 (hu)	2024-11-28
US20190310244A1 (en)	2019-10-10
WO2017081250A1 (en)	2017-05-18
US20190144824A1 (en)	2019-05-16
ES2852998T4 (es)	2024-04-25
CR20220077A (es)	2023-04-11
EP4220360B9 (en)	2024-10-16
BR112018007633A2 (pt)	2018-11-06
ES2852998T3 (es)	2021-09-14
PL4220360T3 (pl)	2024-12-16
CA3004799A1 (en)	2017-05-18
AU2020203573A1 (en)	2020-06-18
MX2022016376A (es)	2023-01-30
NZ741585A (en)	2024-01-26
PE20181157A1 (es)	2018-07-19
DK4220360T3 (da)	2024-09-16
AU2022211910B2 (en)	2024-06-13
US20250389713A1 (en)	2025-12-25
SI3374509T1 (sl)	2021-04-30
HUE053197T2 (hu)	2021-06-28
US10718753B2 (en)	2020-07-21
RU2742007C2 (ru)	2021-02-01
HK1258434A1 (zh)	2019-11-08
CN108291226B (zh)	2022-11-04
AU2023200410B2 (en)	2024-10-31
RS66036B1 (sr)	2024-11-29
CN108350432A (zh)	2018-07-31
HRP20241138T1 (hr)	2024-11-22
IL281211B2 (en)	2024-01-01
CR20180264A (es)	2018-08-06
US20230296587A1 (en)	2023-09-21
CN116064540A (zh)	2023-05-05
JP2018533362A (ja)	2018-11-15
SI4220360T1 (sl)	2024-10-30
CL2018001189A1 (es)	2018-08-31
MX2022016381A (es)	2023-01-30
RS61529B1 (sr)	2021-04-29
EP3798307A1 (en)	2021-03-31
US20170191064A1 (en)	2017-07-06
JP7279000B2 (ja)	2023-05-22
IL258488B (en)	2021-03-25
EP3374498A1 (en)	2018-09-19
EP4220360A3 (en)	2023-08-23
PL3374509T3 (pl)	2021-05-04
KR20180070611A (ko)	2018-06-26
AU2023200410A1 (en)	2023-02-23
WO2017081223A1 (en)	2017-05-18
CL2020000889A1 (es)	2020-08-28

Publication	Publication Date	Title
ES2991800T3 (es)	2024-12-04	Oligonucleótidos para inducir la expresión del UBE3A paterno
US12116576B2 (en)	2024-10-15	Oligonucleotides for modulating SCN9A expression
JP7379387B2 (ja)	2023-11-14	Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
JP7281474B2 (ja)	2023-05-25	Ｔｍｅｍ１０６ｂ発現を調節するためのオリゴヌクレオチド
JP7499267B2 (ja)	2024-06-13	Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
CN118318042A (zh)	2024-07-09	用于调节载脂蛋白e4表达的寡核苷酸
HK40090600A (zh)	2023-11-17	用於诱导父本ube3a表达的寡核苷酸
HK40090602A (zh)	2023-11-17	用於诱导父本ube3a表达的寡核苷酸
JP2021510295A (ja)	2021-04-22	Ｇｓｋ３ｂ発現を調節するためのオリゴヌクレオチド
BR112018007633B1 (pt)	2024-09-24	Oligonucleotídeos para indução de expressão de ube3a paterna
BR122021008010B1 (pt)	2024-10-22	Oligonucleotídeos para indução de expressão de ube3a paterna,conjugado, composição farmacêutica, uso dos mesmos e método para induçãode expressão de ube3a em uma célula alvo onde expressão de ube3a paterna ésuprimida
HK40109677A (zh)	2024-12-06	用於调节载脂蛋白e4表达的寡核苷酸
HK40060810A (en)	2022-05-20	Oligonucleotides for modulating atxn2 expression
HK1253325B (en)	2023-02-24	Oligonucleotides for inducing paternal ube3a expression
CN111615558A (zh)	2020-09-01	用于调节erc1表达的寡核苷酸
HK40043583A (en)	2021-09-17	Oligonucleotides for modulating atxn2 expression
WO2019038228A1 (en)	2019-02-28	OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION